Use of menopausal hormone therapy in the correction of cognitive impairment in menopausal women
- Authors: Gasparyan S.A.1, Drosova L.D.1, Karpov S.M.1, Khripunova A.A.1
-
Affiliations:
- Stavropol State Medical University
- Issue: No 12 (2018)
- Pages: 157-162
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/248390
- DOI: https://doi.org/10.18565/aig.2018.12.157-162
- ID: 248390
Cite item
Open Access
Access granted
Abstract
Objective. To assess changes in cognitive function and quality-of-hfe indicators in menopausal women receiving different types of menopausal hormone therapy (MITT). Subjects and methods. Eighty postmenopausal women with neurovegetative and psychoemotional symptoms were divided into 4 groups: 1) 17-β estradiol 1 mg, drospirenone 2 mg; 2) transdermal 17-β estradiol 0.06% gel, oral micronized progesterone 200 mg; 3) monotherapy with transdermal 17-fi estradiol 0.06% gel; 4) no MET. The Kupperman index, NGF, MoCA test, SF-36 scale, and Beck Depression Inventory were applied to examined the women’s status. Results. NGF levels were significantly increased and the neurovegetative, psychoemotional status improved in Group 1 versus Group 2. Changes were absent in Group 3; cognitive impairment progressed in Group 4. Conclusion. The systemic administration of 17-fi estradiol 1 mg, drospirenone 2 mg versus transdermal 17-fi estradiol 0.06% gel, oral micronized progesterone 200 mg or estrogen monotherapy is effective in restoring cognitive functions and quality of life in early postmenopause.
Full Text
About the authors
Susanna A. Gasparyan
Stavropol State Medical University
Email: Prof-Gasp55@yandex.ru
MD, professor, Department of Obstetrics and Gynecology
Larisa D. Drosova
Stavropol State Medical University
Email: azrunc@bk.ru
postgraduate student of the Department of Obstetrics and Gynecology, Faculty of Postgraduate and Further Education
Sergey M. Karpov
Stavropol State Medical University
Email: karpov25@rambler.ru
MD, Professor head of the Department of neurology, neurosurgery and medical genetics
Alesya A. Khripunova
Stavropol State Medical University
Email: fktcz2007@yandex.ru
Ph.D., Associate Professor, Department of Public Health, Public Health Service and Medical Informatics
References
- Сметник В.П., Сухих Г.Т., Андреева Е.Н., Балан В.Е., Гависова А.А., Григорян О.Р., Ермакова Е.И., Ильина Л.М., Марченко Л.А., Роговская С.И., Сметник А.А., Чернуха Г.Е., Юренева С.В. Менопаузальная гормонотерапия и сохранение здоровья женщин зрелого возраста. Клинические рекомендации: протоколы. Проект. М.; 2014.
- Lobo R.A., Davis S.R., De Villiers T.J., Compel A., Henderson V.W., Hodis H.N. et al. Prevention of diseases after menopause. Climacteric. 2014; 17(5): 540-56.
- Нестрикова Т.Ю., Ячинская T.B. Витамин D. и его роль в формировании постменопаузальных расстройств (обзор литературы). Гинекология. 2015; 17 (4): 19-22.
- Avis N.E., Crawford S.L., Greendale G., Bromberger J.T., Everson-Rose S.A., Gold E.B. et al.; the Study of Women’s Health Across the Nation (SWAN). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern. Med. 2015; 175(4): 531-9.
- McCarrey A.C., Resnick S.M. Postmenopausal hormone therapy and cognition. Horm. Behav. 2015; 74: 167-72.
- Maki P.M. Review article. Verbal memory and menopause. Maturitas. 2015; 82(3): 288-9.
- Gartoulla P., Worsley R., Bell R.J., Davis S.R. Moderate to severe vasomotor and sexual symptoms remain problematic for women aged 60 to 65 year. Menopause. 2015; 22(7): 694-701.
- Weber M.T., Rubin L.H., Maki P.M. Cognition in perimenopause: the effect of transition stage. Menopause. 2013; 20(5): 511-7.
- Baber J., Panay N., Fenton J.A.; the IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy Climacteric. 2016; 19(2): 109-50. doi: 10.3109/13697137.2015.1129166.
- Сухих Г.Т., Сметник В.П., Андреева Е.Н., Балан В.Е., Гависова А.А., Григорян 0.Р., Ермакова Е. И., Зайдиева Я.З., Ильина Л.М., Касян В.Н., Марченко Л.А., Подзолкова Н.М., Роговская С.И., Сметник А.А., Чернуха Г.Е., Юренева С.В. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации (Протокол лечения). М.; 2015.
- Юренева С.В., Дубровина А.В. Применение ультранизких доз препаратов при проведении менопаузальной гормональной терапии. Проблемы репродукции. 2015; 21(3): 122-6.
- Hogervorst Eef. Менопауза: нарушение когнитивной функции и изменения настроения? Consilium medicum. 2015; 17(6): 17-8.
- Gass M.L., Maki P.M., Shifren J.L., Schnatz P.E., Kaunitz A.M., Shapiro М., Sievert L.L. NAMS supports judicious use of systemic hormone therapy for women aged 65 years and older. Menopause. 2015; 22(7): 685-6.
- Mikkola T.S., Tuomikoski P., Lyytinen H., Korhonen P., Hoti E., Vattulainen P. et al. Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy. J. Clin. Endocrinol. Metab. 2015; 100(12): 4588-94.
- Люненфельд Б. Клинические последствия старения женщины. Профилактические стратегии с акцентом на заместительную гормональную терапию. Гинекология. 2014; 16(1): 22-5.
- Юренева С.В., Ильина Л.М., Сметник В.П. Старение репродуктивной системы женщин: от теории к клинической практике. Акушерство и гинекология. 2014; 3: 21-7.
Supplementary files
